Mary Di Biase X4 Pharmaceuticals, Inc (XFOR) insider trading activity

Mary Di Biase is Chief Operating Officer of X4 Pharmaceuticals, Inc. Currently has a direct ownership of 490,980 shares of XFOR, which is worth approximately $260,219. The most recent transaction as insider was on Jan 24, 2025, when has been sold 22,258 shares (Common Stock) at a price of $0.45 per share, resulting in proceeds of $10,016. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 491K

8.61% 3M change

57.95% 12M change

Total Value Held $260,219

Mary DiBiase Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 24 2025	SELL Open market or private sale	$10,016 $0.45 p/Share	22,258 Reduced 4.34%	490,980 Common Stock
Jan 23 2025	BUY Grant, award, or other acquisition	-	61,178 Added 10.65%	513,238 Common Stock
Oct 07 2024	SELL Open market or private sale	$38,586 $0.57 p/Share	67,695 Reduced 13.02%	452,060 Common Stock
Oct 04 2024	BUY Grant, award, or other acquisition	-	230,645 Added 30.74%	519,755 Common Stock
Sep 09 2024	SELL Open market or private sale	$1,743 $0.66 p/Share	2,642 Reduced 0.91%	289,110 Common Stock
Mar 11 2024	SELL Open market or private sale	$13,559 $0.88 p/Share	15,409 Reduced 5.02%	291,752 Common Stock
Feb 12 2024	SELL Open market or private sale	$3,719 $1.01 p/Share	3,683 Reduced 1.18%	307,161 Common Stock
Nov 01 2023	SELL Open market or private sale	$49,417 $0.73 p/Share	67,695 Reduced 17.88%	310,844 Common Stock
Oct 31 2023	BUY Grant, award, or other acquisition	-	230,645 Added 37.86%	378,539 Common Stock
Sep 08 2023	SELL Open market or private sale	$3,302 $1.25 p/Share	2,642 Reduced 1.76%	147,894 Common Stock
Jun 30 2023	SELL Open market or private sale	$876 $1.89 p/Share	464 Reduced 0.31%	150,536 Common Stock
Jun 23 2023	SELL Open market or private sale	$1,654 $1.93 p/Share	857 Reduced 0.56%	151,000 Common Stock
Jun 15 2023	SELL Open market or private sale	$1,911 $2.23 p/Share	857 Reduced 0.56%	151,857 Common Stock
Mar 10 2023	SELL Open market or private sale	$15,281 $0.84 p/Share	18,192 Reduced 10.64%	152,714 Common Stock
Feb 13 2023	SELL Open market or private sale	$4,043 $0.93 p/Share	4,348 Reduced 2.48%	170,906 Common Stock
Aug 17 2022	SELL Open market or private sale	-	1,713 Reduced 0.95%	177,896 Common Stock
Jun 30 2022	SELL Open market or private sale	-	1,578 Reduced 0.87%	179,609 Common Stock
Jun 24 2022	SELL Open market or private sale	-	856 Reduced 0.47%	181,187 Common Stock
Jun 16 2022	SELL Open market or private sale	-	856 Reduced 0.47%	182,043 Common Stock
Mar 01 2022	BUY Grant, award, or other acquisition	-	105,000 Added 36.47%	182,899 Common Stock
Feb 11 2022	SELL Open market or private sale	-	12,545 Reduced 13.87%	77,899 Common Stock
Sep 08 2021	BUY Grant, award, or other acquisition	-	27,000 Added 22.99%	90,444 Common Stock

Mary Di Biase

Chief Operating Officer

Boston, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells XFOR shares.

Notify only if

Value

Insider Trading

Get notified when an X4 Pharmaceuticals, Inc insider buys or sells XFOR shares.

Notify only if

Operation

Value

Type

News

Receive news related to X4 Pharmaceuticals, Inc

Track Activities on XFOR

Account